Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,713 people get REGN articles and Market Currents by email alert.
Get email alerts on REGN »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
at CNBC.com (Jun 3, 2013)
-
at MarketWatch.com (Jun 3, 2013)
-
at CNBC.com (May 14, 2013)
-
PR Newswire (May 8, 2013)
-
at MarketWatch.com (May 3, 2013)
-
PR Newswire (May 3, 2013)
-
PR Newswire (May 3, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (Apr 25, 2013)
-
at CNBC.com (Apr 24, 2013)
-
PR Newswire (Apr 18, 2013)
-
at CNBC.com (Apr 17, 2013)
-
PR Newswire (Apr 4, 2013)
-
at CNBC.com (Mar 28, 2013)
-
at CNBC.com (Mar 15, 2013)
REGN vs. ETF Alternatives
Company Description
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. We currently have one marketed product: ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, September 21, 2012, 2:59 PM Regeneron Pharmaceuticals (REGN -0.7%) announces that the FDA has approved Eylea Injection for the treatment of macular edema. The approval was based on data from Phase 3 studies which showed results for Eylea were superior to those for the sham control group for the primary endpoint. Comment! [Healthcare]
- Thursday, August 23, 2012, 3:21 PM Regeneron (REGN +3.4%) spikes higher once again today on takeover chatter involving Sanofi (SNY -1%). A spokesperson for the company declined to comment, on any takeover talks, noting that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies. SNY is currently REGN's largest shareholder, with a standstill agreement in place that prevents SNY from acquiring more than 30% of REGN. Comment! [Healthcare, On the Move]
- Monday, August 13, 2012, 9:33 AM TheStreet reckons Regeneron (REGN) is a "buy," upgrading it from "hold." The site's Ratings department cites Regeneron's robust revenue, net income and EPS growth, its solid stock price performance, and largely solid financial position. These strengths outweigh Regeneron's weak operating cash flow. Comment! [Quick Ideas, Healthcare]
- Friday, August 3, 2012, 2:36 PM Sanofi (SNY +4.8%) is higher today after the FDA approves Zaltrap, a drug developed by SNY and Regeneron Pharmaceuticals (REGN +1%) for the treatment of advanced colon cancer. Comment! [Healthcare, On the Move]
- Wednesday, August 1, 2012, 8:31 AM The FDA has asked for more information from Regeneron (REGN) about the use of its autoinflammatory drug Arcalyst to treat joint pain caused by gout medicines. The FDA has concerns about Arcalyst's links to cancer. The drug is already approved to treat a rare genetic autoinflammatory disease; extending its use for gout could have added up to $200M a year in sales. Comment! [Healthcare]
- Wednesday, July 25, 2012, 10:35 AM More on Regeneron (REGN) Q2: swings to net profit of $76.7M from loss of $62.5M last year, boosted by sales of its Eylea eye treatment, which surged 57% Q/Q to $194M. Increases FY Eylea sales forecast for the 3rd time, now expecting $700M-$750M vs. $500M-$550M previously. Eylea taking market share from Roche's Lucentis and off-label Avastin. Shares +3.85%. Comment! [Earnings, On the Move, Healthcare]
-
Wednesday, July 25, 2012, 9:16 AM
Premarket gainers: RVBD +26%. ACOM +16%. LL +14%. VHC +13%. INVN +13%. REGN +13%. ALTR +11%. SYMC +10%. DEXO +10%. SPPI +10%. TPX +9%. PSTI +8%. PNRA +8%. GALT +8%. JNPR +7%. ARMH +7%. ALXN +6%. BRCM +6%. STEM +5%.
Losers: RSH -22%. NFLX -20%. TRIP -15%. IGT -12%. BWLD -11%. RFMD -10%. WLP -10%. USG -6%. WFT -6%. Comment! [On the Move] - Wednesday, July 25, 2012, 6:52 AM Regeneron Pharms (REGN): Q2 EPS of $0.90 beats by $0.45. Revenue of $304M (+181.5% Y/Y) beats by $48.02M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, July 25, 2012, 12:05 AM Notable earnings before Wednesday’s open: ALXN, AOL, ARMH, ATI, BA, BMY, CAT, CBE, COP, CP, CVE, DAL, DLR, DRH, ECA, ELN, F, GD, GLW, HCBK, HES, JBLU, LCC, LLY, LO, LVLT, MSI, MT, NDAQ, NLSN, NOC, NYB, OCR, PDS, PEP, PX, REGN, ROK, SO, SWI, TEL, TMO, TROW, UMC, USG, WLP, WYN Comment! [Earnings]
- Tuesday, July 24, 2012, 5:30 PM Notable earnings before Wednesday’s open: ALXN, AOL, ARMH, ATI, BA, BMY, CAT, CBE, COP, CP, CVE, DAL, DLR, DRH, ECA, ELN, F, GD, GLW, HCBK, HES, JBLU, LCC, LLY, LO, LVLT, MSI, MT, NDAQ, NLSN, NOC, NYB, OCR, PDS, PEP, PX, REGN, ROK, SO, SWI, TEL, TMO, TROW, UMC, USG, WLP, WYN Comment! [Earnings]
- Friday, July 20, 2012, 11:17 AM Sanofi (SNY -2%) and Regeneron (REGN -2.5%) today announce that they are enrolling patients in more than 10 late-stage clinical trials , named Odyssey, for a potentially first-in-class cholesterol - lowering drug targeting an enzyme called PCSK9. Odyssey will involve more than 22K patients, including 18K in a trial to measure cardiovascular outcomes such as heart attacks and strokes. Comment! [Healthcare]
- Wednesday, June 13, 2012, 11:04 AM Regeneron (REGN -8.5%) dives after privately-owned Opthotech reports positive Phase 2b results for its Fovista drug. Fovista, working in tandem with Roche's (RHHBY.PK) Lucentis, treats a form of macular degeneration, and stands to compete with Regeneron's Eylea. Lucentis. Jefferies is defending Regeneron, arguing Fovista could just as well work in tandem with Eylea. Comment! [Healthcare, On the Move, Quick Ideas]
- Friday, June 1, 2012, 2:06 PM Cowen's Phil Nadeau says that its latest physician survey suggests sales of Regeneron's (REGN 8.9%) big revenue driver, Eylea, may be slowing. Measuring the uptake of the company's treatment for a leading cause of blindness in the elderly, the number of patients on the drug grew 22% from March to May, compared to 155% growth from January to March. Based on this level of deceleration, Cowen thinks the stock may be rich at these levels. 1 Comment [Healthcare, On the Move]
- Wednesday, May 30, 2012, 1:27 PM Baird defends Regeneron (REGN -2.1%) this morning, saying the drug developer's downstream has significant potential. The firm cites the beginning of REGN's Phase lll testing of REGN727 next month, plus FDA guidance that cardiovascular outcomes will not be a prerequisite for approval. Comment! [Healthcare, On the Move]
- Tuesday, May 8, 2012, 3:44 PM An FDA panel votes unanimously against approval for Regeneron's (REGN -0.1%) Arcalyst, saying it's unsafe for the treatment of gout flares. (transcript) Comment! [Healthcare, Breaking News]
- Friday, April 27, 2012, 11:47 AM Shares of Regeneron (REGN -0.7%) give back a bit after yesterday's blowout quarter on a downgrade to Market Perform by BMO Capital. The firm cites the shares high valuation plus headwinds the company faces from reimbursement hurdles, incremental gains in new switch patients, and existing switch patients transitioning. Comment! [Healthcare]
-
Capitalist Bull
Traditional Technical Patterns completing & readying to #Breakout..$AAPL $GOOG $CLMT $REGN $RYL $BIDU $ALXN $ACT & more http://bit.ly/MwUXlb - View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
freefdawatchlist
http://bit.ly/H6kqQR Bearish Call on SLXP, after rejection from FDA. Expect this stock to decline.fda decision on REGN on Aug 4 - View all 0 replies
-
- View all 3 replies
-
Capitalist Bull: These are the stocks you want to pay attention to for possible setups in the near future.
-
Day Trader001: I get Volume alerts sent to me directly, I guess I just didn't get why you posted them. Thought I was missing something. Thanks
-
- View all 0 replies
-
freefdawatchlist
http://bit.ly/LPYaNG Upcoming FDA approval $AMRN (Jul -26th), $AMRN (Jul - 26th), $SLXP (Jul 27th), $REGN (Aug 4th) - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES